NXTC

NextCure

--(--)

Market Open: --

--(--)

Post-Market: --

Signals Analysis

Buy signal 2

Sell signal 0

consensus rating "Strong Buy"

EPS Beats Expectation

Key Stats

--DAY`S RANGE--

--52 WK RANGE--

Open

Prev.Close

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

Low

52 Week High

52 Week Low

About NXTC

Nextcure, Inc.

A clinical-stage biopharmaceutical company that developing immunomedicines to treat cancer and other immune-related diseases

Industry

Biological Technology

Established Date

Invalid Date

Listing Date

05/09/2019

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.nextcure.com

Security Type

Common stock

Office address

9000 Virginia Manor Road, Suite 200, Beltsville, Maryland 20705

Business

Introduction

NextCure, Inc., incorporated in Delaware in September 2015, is headquartered in Beltsville, Maryland. The company is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel first-in-class immune drugs to treat cancer and other immune-related diseases by restoring normal immune function. Through its proprietary functional, integrated, NextCure Discovery (" FIND-IO ") platform in immuno-oncology, the Company studies a variety of immune cells to discover and understand the targets and structural components of immune cells and their functional effects to develop immunohistochemistry.

Company Financials

EPS

NXTC has released its 2024 Q4 earnings. EPS was reported at -0.42, versus the expected -0.36, missing expectations. The chart below visualizes how NXTC has performed over recent quarters, highlighting trends in earnings surprises.